Sacral Neuromodulation with the InterStim™ System for Intractable Lower Urinary Tract Dysfunctions (SOUNDS): Results of Clinical Effectiveness, Quality of Life, Patient-Reported Outcomes and Safety in a French Multicenter Observational Study.
暂无分享,去创建一个
G. Karsenty | G. Capon | X. Gamé | C. Saussine | E. Chartier-Kastler | A. Ruffion | E. Ragni | L. Peyrat | J. Cornu | G. Stoica | L. Le Normand | F. Dargent | M. Fourmarier | X. Biardeau | E. Brassart | F. Pecoux | A. Melotti | T. Rousseau | J. Graziana | J. Pierrevelcin | N. Berrogain | B. Rabut | P. Bryckaert | Y. Tanneau | A. Abouihia | J. Ferchaud | R. Braguet | Najdat Yaghi | D. Keller
[1] L. Souter,et al. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. , 2019, The Journal of urology.
[2] K. Matzel,et al. Sacral Neuromodulation: Standardized Electrode Placement Technique , 2017, Neuromodulation : journal of the International Neuromodulation Society.
[3] Jeffrey A. Johnson,et al. Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[4] K. Kreder,et al. Detailed analysis of adverse events and surgical interventions in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients , 2017, Neurourology and urodynamics.
[5] H. Zyczynski,et al. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial. , 2016, JAMA.
[6] C. Comiter,et al. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder , 2016, Neurourology and urodynamics.
[7] T. Alexander,et al. The psychological impact of overactive bladder: A systematic review , 2016, Journal of health psychology.
[8] M. Faraday,et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. , 2015, The Journal of urology.
[9] A. Wailoo,et al. A review of the psychometric performance of the EQ-5D in people with urinary incontinence , 2013, Health and Quality of Life Outcomes.
[10] G. Bonsel,et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.
[11] X. Gamé,et al. Neuromodulation sacrée avec le système InterStim™ : résultats du registre national français , 2011 .
[12] Jennifer M Wu,et al. Efficacy and adverse events of sacral nerve stimulation for overactive bladder: A systematic review , 2010, Neurourology and urodynamics.
[13] G. Amarenco,et al. Comprehensive evaluation of bladder and urethral dysfunction symptoms: development and psychometric validation of the Urinary Symptom Profile (USP) questionnaire. , 2008, Urology.
[14] A. Garratt,et al. EuroQol EQ-5D and condition-specific measures of health outcome in women with urinary incontinence: reliability, validity and responsiveness , 2008, Quality of Life Research.
[15] M. Elhilali,et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. , 2007, The Journal of urology.
[16] K. Coyne,et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. , 2006, European urology.
[17] C. Kelleher,et al. The current and future burden and cost of overactive bladder in five European countries. , 2006, European urology.
[18] P. Abrams,et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well‐being in six European countries , 2006, BJU international.
[19] T. Wagner,et al. Health‐related consequences of overactive bladder: an economic perspective , 2005, BJU international.
[20] M. Nichol,et al. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[21] B. Schurch,et al. Buttock Placement of the Implantable Pulse Generator: A New Implantation Technique for Sacral Neuromodulation – A Multicenter Study , 2001, European Urology.
[22] M. Spinelli,et al. Chronic sacral neuromodulation in patients with lower urinary tract symptoms: results from a national register. , 2001, The Journal of urology.
[23] P. Abrams,et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study , 2001, BJU international.
[24] M. Elhilali,et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. , 2000, The Journal of urology.
[25] G. King,et al. Goal Attainment Scaling , 2000 .
[26] Richard A. Schmidt,et al. SACRAL NERVE STIMULATION FOR TREATMENT OF REFRACTORY URINARY URGE INCONTINENCE , 1999 .
[27] G. Amarenco,et al. Une échelle spécifique d'évaluation de la perturbation de la qualité de vie au cours des troubles mictionnels: l'échelle Ditrovie , 1997 .
[28] S. Wexner,et al. Etiology and management of fecal incontinence , 1993, Diseases of the colon and rectum.